Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker price is limiting access to patients and siphoning money away from Medicaid, according ...

It's one of the top healthcare stocks in my portfolio. If I didn't already own this biotech stock, I wouldn't hesitate to buy ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

The best way to beat persistent inflation is to invest in businesses unaffected by rising prices, like these four high-yield ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The biotech industry is ripe with great investment opportunities due to technological advancements such as artificial ...

Super Micro Computer, Inc. (SMCI) stock is on an extended bull run and has more than doubled in 2025. The stock is now the ...

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.